On February 23, 2022 Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, reported that it will release fourth quarter and year-end 2021 financial results Tuesday, March 1, 2022 (Press release, Forma Therapeutics, FEB 23, 2022, View Source [SID1234608907]). Forma management will host an investment community conference call at 8 a.m. Eastern Standard Time (EST), on March 1, 2022 to discuss these financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 3322907. A live webcast of the conference call will be available in the "News & Investors" section of Forma’s website at www.formatherapeutics.com.